Emtricitabine/Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate

恩曲他滨/埃替格韦/考比司他/富马酸替诺福韦二吡呋酯

Report date: 2026/03/18 10:10:44

Base Information

Drug NameEmtricitabine/Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate
Drug Alias NameStribild (TN)埃替格韦/考西司他/富马酸替诺福韦二吡呋酯/恩曲他滨Elvitegravir/cobicistat/emtricitabine/tenofovirElvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabineElvitegravir - cobicistat - emtricitabine - tenofovir disoproxil mixt +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionCytochrome P450 3A inhibitorsReverse transcriptase inhibitorsHuman immunodeficiency virus type 1 reverse transcriptase inhibitors +[5] 
TargetsCytochrome P450 3AHuman immunodeficiency virus type 1 reverse transcriptaseHIV integrase +[5] 
Therapy Area/IndicationsAcquired Immunodeficiency SyndromeHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2012/08/27
Country/TerritoryBelgiumCanadaUnited States +[23] 
CombinationsYes EmtricitabineElvitegravirCobicistat
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences IncGilead Sciences Ireland Uc
Inactive CompaniesRadboud University Medical CenterDuke University
Active IndicationsAcquired Immunodeficiency SyndromeHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ05AR09
Related LinksWikipediaKEGG